Your browser is out-of-date!

Update your browser to view this website correctly.

Disclaimer
To continue, please select your country of domicile and investor type. Depending on your domicile and the investor type that you select, you will have full or restricted access to the information due to legal reasons.

Retail clients: according to Art. 4 Abs. 2 FinSA

Professional/Institutional investors: according to Art. 4 paragraph 3-5 and Art. 5 paragraph 1 and 3-4 FinSA and Art. 10 paragraph 3 and 3ter CISA in conjunction with Art. 6a CISO

Important

Principles 

By using the website www.bbbiotech.com, you confirm that you have read, understood and accepted the general information provided by the BB Biotech AG as well as these legal provisions. These may be subject to change and the use of the site may be restricted or terminated at any time without prior notice.

No recommendation and/or offer for subscription (or for purchase) and/or redemption (or for sale)

The information, products, data, services, tools and documents contained or described on this site ("website content") are for information purposes only and constitute neither an advertisement or recommendation nor an offer or solicitation (to buy) or redemption (sell) investment instruments, to effect any transaction or to enter into any legal relations.

The financial products mentioned on this site are not suitable for all investors. The information contained on this site does not constitute a financial, legal, fiscal or any other recommendation. Investment or other decisions should not be made solely on the basis of this document. In particular, you should not enter into any investment before you have read the corresponding fund agreement or legal prospectus, the annual and semi-annual reports, the articles of association (as far as they are applicable), as well as all other documents, as required in accordance with local legislation or the regulations applied in the legal jurisdictions or countries in which the corresponding investment fund has been licensed or approved for public offer or sale to the public.rlich sind.

The financial products mentioned on this site are not suitable for all investors. The information contained on this site does not constitute a financial, legal, fiscal or any other recommendation. Investment or other decisions should not be made solely on the basis of this document. In particular, you should not enter into any investment before you have read the corresponding fund agreement or legal prospectus, the annual and semi-annual reports, the articles of association (as far as they are applicable), as well as all other documents, as required in accordance with local legislation or the regulations applied in the legal jurisdictions or countries in which the corresponding investment fund has been licensed or approved for public offer or sale to the public.

In order to determine whether the investment in shares of a certain investment fund meets your specific requirements and matches your envisaged risks, we recommend that you contact an independent financial adviser. Furthermore, we recommend that you consult an independent tax adviser in order to obtain information on the tax regulations relating to a specific investment in your legal jurisdiction and with regard to your personal circumstances. In particular tax treatment depends on individual circumstances and may be subject to change.

As the funds are recognised (ie. registered) but not authorised in the UK, the UK Financial Services Authority's financial services compensation scheme does not apply to investments in the fund but the Financial Services Authority regulated firm approving this document for the purposes of UK regulation has taken reasonable steps to satisfy itself that Bellevue will deal in an honest and reliable way and is so satisfied.

Performance

Past performance is not an indication or guarantee of the future performance of the investment. The value of investments may be subject to fluctuations and, under certain circumstances, investors may not get back the full amount invested. The performance data are calculated without taking account of commissions and costs that result from subscriptions and redemptions and commissions and costs have a negative impact on performance. Changes in foreign-exchange rates may also cause the value of investments to go up or down.

Data protection

By accessing this website you state that you agree with the data protection statement. If you do not agree with this statement you should refrain from accessing any further pages of this website. This statement may be updated at any time. We therefore recommend that you check this statement regularly.

Confirmation

By clicking on "Accept", you confirm that you agree to the legal provisions.

This website uses cookies, which are necessary for the technical operation of the website and which are always set. Other cookies to personalize content and analyze access to our website are only set with your consent. We also share information about your use of our website with our social media, advertising and analytics partners.

BB Biotech AG

 
Documents

ISIN-No.: CH0038389992

YTD: -9.82%

Active share: 77.00

Anzahl Positionen: 23

New innovative drugs and technologies are powering sustainable momentum in the biotech sector 

Focus on profitable companies and small and mid-cap companies with strong pipelines

Attractive dividend policy; Dividend payment of 5% p.a.

Indexed performance (as at: 27.06.2025)

Share price: CHF 30.20 (30.06.2025)

NAV: CHF 34.10 (30.06.2025)


01 Jan 2010 - 01 Jan 2010
An error occurred - no data to display
Share Price
NAV
Benchmark

Rolling performance (27.06.2025)

Share PriceNAVBenchmark
30.06.2024 - 30.06.2025-20.39%-18.71%-16.63%
30.06.2023 - 30.06.20247.23%10.15%12.91%
30.06.2022 - 30.06.2023-27.08%-3.49%2.83%
30.06.2021 - 30.06.2022-31.16%-32.36%-24.33%

Annualized performance (27.06.2025)

Share PriceNAVBenchmark
1 year-20.39%-18.71%-16.63%
3 years-14.62%-4.75%-1.38%
5 years-10.92%-7.32%-2.70%
10 years-0.92%-1.97%0.27%
Since Inception p.a.9.03%9.39%8.19%

Cumulative performance (27.06.2025)

Share PriceNAVBenchmark
1M2.90%-0.30%-1.59%
YTD-9.82%-15.31%-13.30%
1 year-20.39%-18.71%-16.63%
3 years-37.75%-13.59%-4.09%
5 years-43.90%-31.64%-12.78%
10 years-8.80%-18.04%2.76%
Since Inception1'443.76%1'608.98%1'108.08%

Annual performance

Share PriceNAVBenchmark
2024-13.53%2.97%7.56%
2023-18.15%-7.39%-4.79%
2022-24.29%-11.00%-9.09%
20218.34%-11.45%2.98%

Investment Focus

BB Biotech actively invests worldwide in fast growing companies developing and marketing innovative biotech drugs. At least 90% of its shareholdings must be in listed companies, while always holding more than 50% of its assets in equity investments. The target portfolio of BB Biotech will generally consist of 20 to 35 participations. Large positions will be taken in five to eight companies, the top holdings. Together they will account for no more than two-thirds of the portfolio and no single position will have a weighting greater than 25% of portfolio investments. Due to their substantial portfolio weighting, the top holdings should be generating both revenues and income. The portfolio’s smaller participations are companies with promising drug candidates in their R&D pipelines. Investments are selected according to a thorough, multi-level due diligence process, with a particular focus placed on the analysis of financial parameters, the respective competitive environment, the development pipeline, the patent portfolio, and end-client perception. ESG factors are taken into consideration while implementing the aforementioned investment objectives.Show moreShow less

Investment suitability & Risk

SRI

Low risk

High risk

The investment company’s objective is to generate attractive and competitive capital growth in the long term. It is therefore particularly suited to investors with an investment horizon of at least 5 years who want to selectively diversify their portfolio with investments in the biotechnology sector and who are willing to accept the equity risks typical of this sector.

General Information

Investment ManagerBellevue Asset Management AG
CustodianBank Julius Bär AG
Fund AdministratorBellevue Asset Management AG
AuditorDeloitte AG
Launch date09.11.1993
Year end closing31. Dec
Management Fee1.10%
ISIN numberCH0038389992
Valor number3838999
BloombergBION SW Equity
WKNA0NFN3

Legal Information

Legal formIncorporate company
SFDR categoryArticle 8

Key data (31.05.2025, base currency CHF)

Beta1.23
Volatility29.96
Tracking error13.68
Active share77.00
Correlation0.91
Sharpe ratio0.06
Information ratio0.17
Jensen's alpha2.37
No. of positions23

Positions

Argenx
Ionis Pharmaceuticals
Alnylam Pharmaceuticals
Neurocrine Biosciences
Vertex Pharmaceuticals
Revolution Medicines
Incyte
Agios Pharmaceuticals
Scholar Rock Holding
Celldex Therapeutics
Rivus Pharmaceuticals, Inc.
Akero Therapeutics
Biohaven Ltd
Beam Therapeutic
Moderna
Immunocore
Wave Life Sciences Ltd.
Edgewise Therapeutics Inc
Relay Therapeutics
Esperion
Macrogenics
Annexon Inc
Black Diamond Therapeutics
16.2%
11.3%
9.8%
9.6%
9.2%
7.4%
6.0%
4.9%
3.8%
2.7%
2.6%
2.4%
2.3%
2.2%
2.0%
1.7%
1.6%
1.5%
0.9%
0.7%
0.6%
0.5%
0.2%

Market capitalization

0 - 500mn
1 - 5 bn
5 - 30 bn
> 30 bn
5.5%
34.4%
25.0%
35.2%

Breakdown by sector

Small Molecule
Biologics
RNA
Gene- and cell therapy
45.7%
27.4%
24.6%
2.2%

Currency

USD
100.0%

Benefits

  • Unique opportunity for European investors to access the global biotech sector, a non-cyclical growth industry that is strongly supported by increasing demand, driven by demographic trends and life style changes.
  • New innovative drugs and technologies are powering sustainable momentum in the biotech sector.
  • Focus on a diversified portfolio of profitable companies as well as small and midcap companies with strong pipelines.
  • Management Team with strong scientific and medical expertise. Renowned Board of Directors.
  • Attractive dividend policy; Dividend payment of 5% p.a.

Risks

  • BB Biotech actively invests in equities. Equities are subject to strong price fluctuations and so are also exposed to the risk of price losses.
  • Biotech equities can be subject to sudden substantial price movements owning to market, sector or company factors.
  • BB Biotech invests in foreign currencies, which means a corresponding degree of currency risk against the reference currency.
  • The price investors pay or receive, like other listed shares, is determined by supply and demand and may be at a discount or premium to the underlying net asset value of the Company.
  • BB Biotech may take a leverage of up to 15%, which may lead to even higher price movements compared to the underlying market.

In May BB Biotech´s share price declined by 0.7% in CHF and the Net Asset Value declined by 1.0% in USD. The Nasdaq Biotech Index declined by 4.1% in USD in May.    
 
We are still seeing fundamental progress in most of our portfolio companies. Our strategy focuses on companies pursuing transformative approaches in areas with high unmet medical needs. We are operating with increased caution. The US regulatory landscape has become more unpredictable. In this context, we are intensifying engagement with our portfolio companies to ensure preparedness across financing, manufacturing and supply chains, clinical development plans, regulatory pathways, and commercial execution. 
 
We continue to prioritize long-term value creation by investing in deeply differentiated products and companies with clear clinical and commercial pathways. We are backing companies with sharpened investment hypotheses, improved risk-adjusted entry points, and greater capital discipline. Structural changes may take time to settle, but we view this period as one of strategic positioning.  
 
Please find below selected highlights from a few of BB Biotech´s portfolio companies:  
 
Incyte (+3.8%, in USD) announced on May 15 that the FDA has approved Zynyz® (retifanlimab-dlwr) in combination with carboplatin and paclitaxel (chemotherapy) for the first-line treatment of adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal (SCAC). In addition, the FDA granted approval for Zynyz as a single agent for the treatment of adult patients with locally recurrent or with metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy. 
 
Revolution Medicines (-2.4%, in USD) announced on May 14 that the first patient has been dosed in RASolve 301, a global, randomized, open-label Phase III clinical trial. RASolve 301 will evaluate the safety and efficacy of daraxonrasib (RMC-6236) in patients with previously treated, locally advanced or metastatic RAS mutant non-small cell lung cancer (NSCLC) compared to docetaxel chemotherapy. 

Argenx (-11.1%, in USD) announced on May 8 first quarter results and a business update. Argenx generated global product net sales (inclusive of both VYVGART and VYVGART SC) of USD 790 mn in the first quarter of 2025. Multiple regulatory decisions on approval for PFS are completed or underway: Positive recommendation from Committee for Medicinal Products for Human Use (CHMP) of European Medicines Agency (EMA) for VYVGART-SC (PFS and vial) for CIDP.  

Loading...

Show moreShow less

ESG

  • Head Investment Management Team

    Christian Koch

    Dr Christian Koch has been a portfolio manager at Bellevue Asset Management since 2014. From 2013-2014 he was a sell-side Pharma & Biotech equity analyst at Bank am Bellevue in Küsnacht and from 2010-2013 a Research Associate at the Institute of Pharmaceutical Sciences at ETH Zurich. He holds a PhD in Computer-Assisted Drug Design from ETH Zurich and studied Bioinformatics from Goethe University Frankfurt.

  • Deputy Head Investment Management Team

    Maurizio Bernasconi

    Dr. Maurizio Bernasconi joined Bellevue Asset Management as analyst and portfolio manager in 2017. Prior he was a sell-side equity analyst in the Pharma & Biotech department of Bank am Bellevue. Maurizio Bernansconi has a master's degree in chemistry at Swiss Federal Institute of Technology (ETH), Zurich, and has PhD in organic chemistry at the University of Basel.

  • Investment Management Team

    Anna Guinot Aguado

    Dr. Anna Guinot Aguado joined Bellevue Asset Management in 2024. She previously worked at Nextech Invest, a European Biotech VC focused on oncology, where she gained investment experience in both private and public markets. Before her time at Nextech, Anna completed a PostDoc at the University Children's Hospital Zurich (Kispi) in the Oncology division and at the institute of physiology at the University of Zurich. She holds a PhD in Stem Cell & Cancer Biology from the University of Cambridge, after studying Biochemistry in Valencia and Molecular & Cell Biology in Paris.

  • Investment Management Team

    Leonidas Georgiou

    Dr. Leonidas Georgiou joined Bellevue Asset Management as a portfolio manager in 2022. He previously worked as a biotechnology VC analyst at Hadean Ventures in Norway, covering European startups in pharma, medical device, diagnostic and digital health verticals. Leonidas studied neuroscience at the University of Glasgow and University of Toronto. He holds an interdisciplinary PhD in neuroscience from OIST in Japan where he studied neuron – glia interactions in behaving mice.

  • Data Scientist

    Can Buldun-Gora

    Dr. Can Buldun-Gora joined Bellevue Asset Management as Data Scientist in 2022. He is a member of the investment management team of BB Biotech. From 2018 to 2022 he was a Computational Scientist at Roche Pharma Research & Early Development, focusing on data science and software solutions for next-generation antibody engineering. Can Buldun-Gora holds a PhD in Biochemistry from the University of Oxford and a BSc in Biochemistry & Cell Biology from Jacobs University Bremen.

  • Data Scientist

    Olivia Woolley

    Dr. Olivia Woolley joined Bellevue Asset Management as data scientist in 2022. She is a member of the investment management team of BB Biotech. Previously she was associate director data science at Novartis, working in Technical Research and Development. Before entering industry she was a postdoctoral researcher at the Swiss Federal Institute of Technology (ETH), Zurich, in the area of digital epidemiology and complex networks. Olivia holds a PhD and MSc in Applied Mathematics from Northwestern University and a BSc in Mathematical and Computational Science from Stanford University.

  • Data Scientist

    Samuel Croset

    Dr. Samuel Croset joined Bellevue Asset Management as Portfolio Manager and Digital Transformation Lead in 2020. He previously worked for Roivant Sciences from 2018-2020 as data scientist supporting investment decisions in drug projects as well as leading a team focused on the analysis of real-world data. Prior to that, he started his professional career at Roche as data scientist in the research department (2014-2018). Samuel holds a Ph.D. in Bioinformatics from the University of Cambridge, a MS in Bioinformatics and a MS in Biochemistry from the University of Geneva.
1

These insights might interest you